-
GeoVax Positions GEO-MVA to Address Supply Constraints in Global Mpox and Smallpox Vaccine Market
Highlights Critical Need for Additional MVA Vaccine Supply, Ending the Current Monopoly, Increasing Access and Supply Worldwide ATLANTA, GA, April 14, 2026 – GeoVax…
-
GeoVax Highlights Single-Dose Mpox Vaccine Data at World Vaccine Congress 2026
MVA-X Platform Demonstrates Single-Dose Durable Protection Comparable to Two-Dose Regimen ATLANTA, GA, April 2, 2026 – GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company…
-
GeoVax Announces a Warrant Inducement Transaction
ATLANTA, GA – March 31, 2026 (NEWMEDIAWIRE) – GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing vaccines and immunotherapies against infectious…
-
GeoVax Provides Update on GEO-MVA Program
Clinical Product Release Testing Completed in Support of Pivotal Phase 3 Trial Atlanta, GA – March 25, 2026 – GeoVax Labs, Inc. (Nasdaq: GOVX),…
-
GeoVax Announces European Society of Medicine Publication Highlighting GEO-CM04S1 as a Next-Generation COVID-19 Vaccine for Immunocompromised Patients
Peer-Reviewed Article Describes Clinical and Immunologic Rationale for Dual-Antigen MVA-Based Vaccine Designed to Address Limitations of First-Generation COVID-19 Vaccines in Highly Vulnerable Populations…
-
GeoVax Initiates Outreach Regarding Future Procurement of GEO-MVA Mpox/Smallpox Vaccine
Program Reaches Strategic Inflection Point as GEO-MVA Advances Toward Pivotal Phase 3 Study Atlanta, GA – March 11, 2026 – GeoVax Labs, Inc. (Nasdaq:…
-
GeoVax Announces Oncology Advisory Board to Advance Gedeptin® Development Across Solid Tumors
Members Bring Deep Expertise in Immuno-Oncology, Translational Medicine, and Checkpoint Inhibitor Combination Strategies ATLANTA, GA – February 24, 2026 – GeoVax Labs, Inc. (Nasdaq:…
-
GeoVax Secures Exclusive License for Gedeptin® + Immune Checkpoint Inhibitor Combination Technology
License Strengthens GeoVax’s Immuno-Oncology Strategy and Expands Intellectual Property Foundation for Combination Therapies Across Solid Tumors ATLANTA, GA – February 18, 2026 – GeoVax…
-
GeoVax Endorses Global Call to Sustain Mpox Response as Evidence Confirms Epidemic Is Far from Over
Company Highlights GEO-MVA Manufacturing Readiness and Clear Clinical Pathway to Support Global Supply Diversification ATLANTA, GA – February 17, 2026 – GeoVax Labs, Inc.…
-
GeoVax Labs Announces $1 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
ATLANTA, GA, February 13, 2026 – GeoVax Labs, Inc. (Nasdaq: GOVX) (the “Company”), a clinical-stage biotechnology company developing immunotherapies and vaccines against cancer and…
-
GeoVax Highlights 2026 as a Pivotal Year for Progress
Management Highlights 2026 as a Portfolio-Wide Inflection Year Driven by Regulatory De-Risking, Clinical Readouts, and Scalable Manufacturing ATLANTA, GA – January 20, 2026 –…
-
GeoVax Announces 1-for-25 Reverse Stock Split to Regain Compliance with Nasdaq Minimum Bid Requirement
Atlanta, GA, January 8, 2026 – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today…